Chimeric cytoplasmic signalling molecules
Nucleic acids are described which code for chimeric cytoplasmic signalling molecules containing at least one cytoplasmic signalling sequence derived from CD134 or ICOS. The nucleic acids may be expressed in cells to produce chimeric receptors and other proteins which are able to regulate cell activation processes. Such regulated cells are of use in medicine, for example in the treatment of infectious, inflammatory and autoimmune diseases.
1 . A nucleic acid molecule comprising a sequence encoding a cytoplasmic signalling molecule that comprises at least two cytoplasmic signalling sequences, wherein at least one of the cytoplasmic signalling sequences is derived from CD134 or the human inducible co-stimulator.
2 . A nucleic acid molecule according to claim 1 , wherein at least one of the cytoplasmic signalling sequences is a primary cytoplasmic signalling sequence.
3 - 5 . (canceled)
6 . A nucleic acid molecule according to claim 1 , wherein at least one of the cytoplasmic signalling sequences is a secondary cytoplasmic signalling sequence.
7 . (canceled)
8 . A nucleic acid molecule according to claim 2 , comprising a sequence encoding a cytoplasmic signaling molecule that comprises three cytoplasmic signalling sequences.
9 . A nucleic acid molecule according to claim 2 , wherein the first cytoplasmic signalling sequence encoded in a reading frame is derived from CD134 or the human inducible co-stimulator.
10 . A nucleic acid molecule according to claim 9 , which encodes i) a cytoplasmic signalling sequence derived from CD134 followed in a reading frame by ii) a cytoplasmic signalling sequence derived from TCRζ.
11 . A nucleic acid molecule according to claim 9 , which encodes i) a cytoplasmic signalling sequence derived from the human inducible co-stimulator followed in a reading frame by ii) a cytoplasmic signalling sequence derived from TCRζ.
12 . A nucleic acid molecule according to claim 2 , wherein the second cytoplasmic signalling sequence encoded in a reading frame is derived from CD134 or the human inducible co-stimulator.
13 - 15 . (canceled)
16 . A nucleic acid molecule according to claim 8 which encodes in a reading frame i) a cytoplasmic signalling sequence derived from CD28, ii) a cytoplasmic signalling domain derived from TCRζ, and iii) a cytoplasmic signalling sequence derived from CD134.
17 . A nucleic acid molecule according to claim 8 which encodes in a reading frame i) a cytoplasmic signalling sequence derived from CD28, ii) a cytoplasmic signalling domain derived from TCRζ, and iii) a cytoplasmic signalling sequence derived from the human inducible co-stimulator.
18 . A nucleic acid molecule encoding a chimeric receptor protein, which comprises an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic signalling domain, wherein the cytoplasmic signalling domain is encoded by a nucleic acid sequence according to claim 1 .
19 . A nucleic acid molecule encoding a chimeric receptor protein, which comprises an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic signalling domain, wherein the cytoplasmic signalling domain comprises a single cytoplasmic signalling sequence derived from CD134 or the human inducible co-stimulator.
20 . (canceled)
21 . A nucleic acid molecule according to claim 18 wherein the extracellular ligand-binding domain is an antibody, or an antigen-binding fragment thereof.
22 - 24 . (canceled)
25 . A vector comprising a nucleic acid molecule according to claim 1 .
26 . A host cell containing a nucleic acid molecule according to claim 1 .
27 . (canceled)
28 . A chimeric receptor protein encoded by a nucleic acid molecule according to claim 18 .
29 . (canceled)
30 . A host cell according to claim 26 , which is a resting or senescent T-lymphocyte.
31 - 34 . (canceled)
35 . A method for treating HIV infection, asthma, eczema, cystic fibrosis, sickle cell anemia, psoriasis, multiple sclerosis, organ transplant rejection, graft-versus-host disease, diabetes, or cancer comprising administering to a patient suffering from such a disease or disorder a therapeutically effective amount of a nucleic acid molecule according to claim 1 .
36 . A method for treating HIV infection, asthma, eczema, cystic fibrosis, sickle cell anemia, psoriasis, multiple sclerosis, organ transplant rejection, graft-versus-host disease, diabetes, or cancer comprising administering to a patient suffering from such a disease or disorder a therapeutically effective amount of a nucleic acid molecule according to claim 18 .
37 . A composition comprising a nucleic acid molecule according to claim 1 in conjunction with a pharmaceutically acceptable excipient.